dihexa approval status fda Buy 15mg | Third-Party Tested DIHEXA 10MG : COA Tested

We think the July meeting is genuinely significant

The FDAs category-2 page says GHK-Cu has been withdrawn from category 2, and the agency plans to consult PCAC about it before the end of February 2027

Regulatory submissions are anticipated, with a potential approval timeline of 20262027 if the process proceeds smoothly

Research-Referenced Functional Attributes (Based on existing preclinical and literature datanot intended as claims of therapeutic use) High-affinity binding to HGF and potentiation of c-Met activation in the presence of subthreshold HGF concentrations in cellular assays (DOI: 10.1124/jpet.114.218735) Induction of synaptogenesis and dendritic spine formation through HGF/c-Met pathway augmentation in neuronal models Observation of PI3K/AKT signaling modulation in APP/PS1 mouse models (DOI: 10.3389/fnagi.2021.748253) Investigation of neuroregenerative signaling mechanisms in scopolamine-induced impairment paradigms Examination of synaptic protein expression markers in aging or stress-challenged experimental systems Examination of oral bioavailability and blood-brain barrier penetration in rodent studies

Antinociceptive properties help reduce pain associated with inflammatory processes